Bibliographic Citation
| - Aparicio T., Lavau-Denes S., Phelip J.M., Maillard E., Jouve J.L., Gargot D., Gasmi M., Locher C., Adhoute X., Michel P., Khemissa F., Lecomte T., Provençal J., Breysacher G., Legoux J.L., Lepère C., Charneau J., Crétin J., Chone L., Azzedine A., Bouché O., Sobhani I., Bedenne L., Mitry E., Investigators FFCD. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02). Annals of Oncology, Elsevier, 2016, 27 (1), pp.121 - 127. ⟨10.1093/annonc/mdv491⟩
- Aparicio T., Lavau-Denes S., Phelip J.M., Maillard E., Jouve J.L., Gargot D., Gasmi M., Locher C., Adhoute X., Michel P., Khemissa F., Lecomte T., Provençal J., Breysacher G., Legoux J.L., Lepère C., Charneau J., Crétin J., Chone L., Azzedine A., Bouché O., Sobhani I., Bedenne L., Mitry E.. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02). Annals of Oncology, Elsevier, 2016, 27 (1), pp.121 - 127. ⟨10.1093/annonc/mdv491⟩
|